Visual Abstract

Background: Effective actions to slow chronic kidney disease (CKD) progression depend on early disease recognition. This study aimed to assess the prevalence of and factors associated with undiagnosed stage 3 CKD.

Methods: REVEAL-CKD is a multinational initiative to assess undiagnosed CKD. From the US, we utilised TriNetX, a federated research network providing statistics on electronic health records. Adult patients, with two eGFR measurements ≥30 and <60 mL/min/1.732 at least 90 days apart, were identified between 2015-2020. The date of the second eGFR measurement was defined as the index date. Those with no CKD diagnosis code at any time before or up to 6 months after the index date were considered to have undiagnosed CKD.

Results: The study cohort included 178,331 patients whose mean age at index date was 70.8 years (standard deviation (SD): 10.6). The proportion of patients with undiagnosed CKD was 62.4% (95% confidence interval [CI] 62.2 to 62.6). Patients with comorbidities or younger age had a lower undiagnosed rate (Table 1). Of 123,994 patients with undiagnosed CKD at the index date, 25% received a diagnosis at some point during follow-up, with a median time to diagnosis of 253 days.

Conclusion: This study documented that a majority of stage 3 CKD patients were undiagnosed. These results suggest that an opportunity exists for more proactive CKD diagnosis and monitoring at early stages.

Disclosure

A. Abdul sultan: Employee; Self; AstraZeneca. S. Barone: Employee; Self; AstraZeneca. S. Kumar: Employee; Self; AstraZeneca, Stock/Shareholder; Self; AstraZeneca. H. Chen: None. K. Järbrink: Employee; Self; AstraZeneca. E. T. Wittbrodt: Employee; Self; AstraZeneca, Stock/Shareholder; Self; AstraZeneca. P. R. Kushner: Advisory Panel; Self; Abbott Diabetes, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Janssen Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.